Skip to content
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Nephrology

Specialist-Directed Supportive Treatment

At a Glance

Fanconi renotubular syndrome 3 has no treatment that corrects the EHHADH mutation, so nephrology teams replace lost bicarbonate, phosphate, and potassium. Lifelong blood, urine, and kidney ultrasound monitoring helps balance treatment benefits with risks such as high urine calcium and kidney stones.

There is currently no cure or specific treatment that targets the EHHADH genetic mutation itself [1]. Instead, management relies on specialist-directed supportive care that is extrapolated from the general treatment of Fanconi syndrome, proximal renal tubular acidosis (RTA), and phosphate-wasting conditions [2]. This means your medical team works to “fill the gap” by replacing exactly what your kidneys are losing into the urine [3].

Important Safety Warning: Never start, stop, or independently adjust the doses of potassium, phosphate, bicarbonate, citrate, or active vitamin D. Both deficiency and over-replacement can be dangerous, especially if your kidney function changes. Always consult your nephrology team before making any changes.

Because the disease varies widely—even between family members—there is no single “correct” dose for everyone [1][4]. Your treatment plan will be uniquely tailored based on your blood and urine tests [5].

Managing Acidosis (Alkali Therapy)

In FRTS3, the kidneys fail to reclaim bicarbonate, which helps balance the acid in your blood. This results in proximal renal tubular acidosis (RTA) [6].

  • The Treatment: Doctors may prescribe oral alkali therapy, usually in the form of sodium bicarbonate or potassium citrate [7][2].
  • The Challenge: Proximal RTA can require high doses of alkali because the kidneys waste a large portion of it back into the urine [2]. You may need to take these supplements several times a day.

Protecting Bone Health

Low blood phosphate (hypophosphatemia) is a significant concern, as it can lead to rickets in children or osteomalacia (bone softening) in adults [1][8].

  • Phosphate Supplements: You may be prescribed oral phosphate, often taken in several divided doses throughout the day to keep levels steady [9][10].
  • Active Vitamin D: If clinically indicated by your calcium, phosphate, and PTH levels, doctors may prescribe “active” forms of vitamin D, such as calcitriol or alfacalcidol, to help your body absorb phosphate and calcium [10][11]. Note that this is a selected therapy, and it is different from the over-the-counter vitamin D3 found in most stores [11].

Potassium Replacement

Many people with Fanconi syndrome lose large amounts of potassium in their urine [3].

  • The Treatment: If your blood potassium levels are low, you may need potassium supplements [3].
  • Important Note: Potassium must be carefully monitored and directed by a physician, as levels that are too high or too low can both affect heart rhythm [2][12].

Balancing Benefits and Risks

While replacing lost minerals is essential, it requires a delicate balance. Taking phosphate and active vitamin D can contribute to complications if not closely monitored [9][13].

  • Hypercalciuria: This occurs when there is too much calcium in the urine [14].
  • Nephrocalcinosis: If calcium levels in the urine remain high, calcium deposits can form in the kidney tissue (nephrocalcinosis) or develop into kidney stones (nephrolithiasis) [14][15].

To minimize these risks, your doctor will check your urine calcium levels and may perform periodic renal ultrasounds to look for early signs of mineral buildup [12][14].

Life-Long Monitoring

Because FRTS3 is a chronic condition, treatment is usually lifelong. If you have a stomach bug, vomiting, or diarrhea and cannot keep your oral supplements down, follow your written sick-day plan or contact your medical team immediately, as you may need intravenous (IV) fluids to prevent a rapid drop in your electrolyte levels [16].

Common questions in this guide

What is the main treatment for Fanconi renotubular syndrome 3?
There is no current treatment that corrects the EHHADH mutation itself. Care is specialist-directed and replaces substances lost in urine, such as bicarbonate, phosphate, and potassium, with doses adjusted to blood and urine results.
Why might I need sodium bicarbonate or potassium citrate for FRTS3?
FRTS3 can cause proximal renal tubular acidosis because the kidneys lose bicarbonate. Sodium bicarbonate or potassium citrate supplies alkali to help balance blood acidity, and proximal renal tubular acidosis may require several doses each day.
How is low phosphate treated in FRTS3?
Doctors may prescribe oral phosphate in divided doses to improve low blood phosphate and support bone health. If calcium, phosphate, and parathyroid hormone results indicate it, they may also prescribe active vitamin D such as calcitriol or alfacalcidol.
Why must potassium and other supplements be monitored closely?
Too little or too much potassium can disturb heart rhythm, especially when kidney function changes. Blood and urine testing helps clinicians adjust potassium, bicarbonate, phosphate, and active vitamin D safely, so patients should not change doses independently.
What kidney problems can FRTS3 treatment cause?
Phosphate and active vitamin D can sometimes raise urine calcium, a condition called hypercalciuria. Persistent high urine calcium can contribute to calcium deposits in the kidneys or kidney stones, so clinicians may check urine calcium and perform periodic kidney ultrasounds.
What should I do if vomiting or diarrhea prevents me from taking my supplements?
Follow your written sick-day plan and contact your medical team promptly rather than changing doses on your own. If oral supplements cannot be kept down, intravenous fluids may be needed to prevent a rapid fall in electrolyte levels.

Get notified when new evidence is published on Fanconi renotubular syndrome 3.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (16)
  1. 1

    A puzzling renal Fanconi syndrome.

    Haydock L, Hureaux M, Hoffmann M, et al.

    Clinical kidney journal 2025; (18(8)):sfae408 doi:10.1093/ckj/sfae408.

    PMID: 40800210
  2. 2

    Renal Tubular Acidosis.

    Bagga A, Sinha A

    Indian journal of pediatrics 2020; (87(9)):733-744 doi:10.1007/s12098-020-03318-8.

    PMID: 32591997
  3. 3

    Fanconi Syndrome.

    Foreman JW

    Pediatric clinics of North America 2019; (66(1)):159-167 doi:10.1016/j.pcl.2018.09.002.

    PMID: 30454741
  4. 4

    The recurrent p.Glu3Lys variant in EHHADH is responsible for Fanconi syndrome with early liver dysfunction and mitochondrial abnormalities.

    Rollier P, Cospain A, Barth M, et al.

    Molecular genetics and metabolism reports 2025; (43()):101214 doi:10.1016/j.ymgmr.2025.101214.

    PMID: 40242153
  5. 5

    Proximal renal tubular acidosis with and without Fanconi syndrome.

    Kashoor I, Batlle D

    Kidney research and clinical practice 2019; (38(3)):267-281 doi:10.23876/j.krcp.19.056.

    PMID: 31474092
  6. 6

    A review of renal tubular acidosis.

    Kunchur MG, Mauch TJ, Parkanzky M, Rahilly LJ

    Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001) 2024; (34(4)):325-355 doi:10.1111/vec.13407.

    PMID: 39023331
  7. 7

    Adult-Onset Fanconi Syndrome Presenting as Stress Fractures: A Case Report.

    Gupta S, Kamat N, Shenoy DV, Agarwal S

    Journal of orthopaedic case reports 2025; (15(12)):32-35 doi:10.13107/jocr.2025.v15.i12.6444.

    PMID: 41509769
  8. 8

    Understanding renal tubular acidosis.

    Wang SSY, Tang H, Ho WQJ, et al.

    British journal of hospital medicine (London, England : 2005) 2024; (85(10)):1-12 doi:10.12968/hmed.2024.0290.

    PMID: 39475030
  9. 9

    Rickets guidance: part II-management.

    Haffner D, Leifheit-Nestler M, Grund A, Schnabel D

    Pediatric nephrology (Berlin, Germany) 2022; (37(10)):2289-2302 doi:10.1007/s00467-022-05505-5.

    PMID: 35352187
  10. 10

    Cystinosis-associated metabolic bone disease: pathogenesis and outcome.

    Schön A, Szaroszyk M, Haffner D

    Pediatric nephrology (Berlin, Germany) 2026; doi:10.1007/s00467-026-07518-w.

    PMID: 42697975
  11. 11

    Severe Hypophosphatemia as the Initial Presentation of Renal Fanconi's Syndrome and Distal Renal Tubular Acidosis Related to Zoledronic Acid: A Case Report and Literature Review.

    Wu Y, Ma T, Yu X, Su T

    Kidney & blood pressure research 2023; (48(1)):18-27 doi:10.1159/000527931.

    PMID: 36412607
  12. 12

    Management of bone disease in cystinosis: Statement from an international conference.

    Hohenfellner K, Rauch F, Ariceta G, et al.

    Journal of inherited metabolic disease 2019; (42(5)):1019-1029 doi:10.1002/jimd.12134.

    PMID: 31177550
  13. 13

    Adefovir dipivoxil-induced Fanconi syndrome and its predictive factors: A study of 28 cases.

    Lin Y, Pan F, Wang Y, et al.

    Oncology letters 2017; (13(1)):307-314 doi:10.3892/ol.2016.5393.

    PMID: 28123560
  14. 14

    Skeletal Consequences of Nephropathic Cystinosis.

    Florenzano P, Ferreira C, Nesterova G, et al.

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2018; (33(10)):1870-1880 doi:10.1002/jbmr.3522.

    PMID: 29905968
  15. 15

    Nephrolithiasis and Osteomalacia associated with adefovir-induced Fanconi syndrome in a patient with hepatitis B.

    Lin J, Zhuo Y, Zhang D

    BMC nephrology 2017; (18(1)):275 doi:10.1186/s12882-017-0693-4.

    PMID: 28851305
  16. 16

    Fanconi syndrome, diabetes insipidus, and acute kidney injury due to tenofovir disoproxil fumarate: A case report.

    Zilwa N, Mpejane O, Mehboob G, et al.

    Antiviral therapy 2023; (28(3)):13596535231186727 doi:10.1177/13596535231186727.

    PMID: 37368845

This page is for informational purposes only and does not replace medical advice. It explains FRTS3 supportive treatment, but your nephrology team must guide supplement doses, monitoring, and sick-day plans.